The administration of low doses of recombinant interleukin-2 (rll-2) in vivo to patients with malignant neoplasms has been demonstrated to selectively increase the number of circulating natural killer (NK) cells in these patients. Recent evidence from SCID mouse models suggests that IgG subclass levels can be influenced by the presence and activity of NK cells. Therefore, we sought to examine the effect of rll-2 infusions on human serum IgG subclass concentrations. We determined serum IgG subclass concentrations in 27 cancer patients receiving low-dose rlL-2 by daily continuous intravenous infusion. Eleven of these patients had active, metastatic, nonhematologic tumors; 16 patients had received IL-2 when they were in a minimal residual disease state after autologous or allogeneic bone marrow trans-C YTOKINES ARE KNOWN to influence IgG subclass concentrations in murine systems. Both y-interferon (IFN-7) and interleukin-4 (IL-4) play critical roles in regulating isotype switching. IFN-y induces IgG2a immunoglobulin both in vitro and in vivo, and IL-4 selectively stimulates IgGl and IgE secretion."' The recognition that IL-4 and IFN-7 are involved in murine IgG subclass regulation and isotype selection has led investigators to focus on the cell types that elaborate these cytokines. Although significant attention has been paid to helper T-cell subsets, other cells producing cytokines [macrophages, activated B cells, and natural killer (NK) cells] may contribute to IgG subclass selection. Indeed, NK cells have recently been demonstrated to play a role in regulating murine immunoglobulin production.6
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MATERIALS AND METHODS

Patient
had evidence of metastatic cancer demonstrable either by physical exam or a radiographic imaging study. Eligibility criteria also included age greater than 18 years: ECOG performance status 0 to 2; normal or near normal parameters of renal, hepatic, and pulmonary function; and life expectancy exceeding 3 months. Patients were not receiving concurrent chemotherapy or radiotherapy while undergoing treatment with IL-2. The second group of patients consisted of 16 individuals who had undergone either autologous, syngeneic, or allogeneic bone marrow transplantation (BMT) for hematologic or nonhematologic malignancy. Patients were eligible to receive IL-2 therapy if at least 6 weeks had elapsed since marrow infusion. Patients could have no evidence of grades 2 to 4 graft-versus-host disease (GVHD) and could bi taking no immune suppressive medication during IL-2 therapy. No patients received intravenous immunoglobulin either before or during IL-2 therapy. Again, patients were required to have ECOG performance status 0 to 2 and normal or near normal parameters of renal, hepatic, and pulmonary function before initiating IL-2.
IL-2 treatment. Both groups of patients received rIL-2 (Hoffmann-LaRoche, Nutley, NJ) by continuous intravenous infusion through an indwelling central catheter in an outpatient setting. Drug was administered by a portable computerized ambulatory pump Immunophenotypic studies. PBMC obtained before beginning [L-2 and after approximately 8 to 10 weeks of treatment were assayed for surface immunophenotypic markers. PBMC were obtained after Ficoll-Hypaque density gradient sedimentation and were analyzed by direct immunofluorescence for reactivity with a series of monoclonal antibodies using standard techniques. Cells were analyzed for reactivity with a panel of monoclonal antibodies, including T3 (CD3), T4 (CD4), T8 (CD@, NKH 1 (CDS6), B I (CD20), and FcyIII receptor (CD16) (Coulter Immunology, Hialeah, FL). Singleand dual-color immunofluorescence reactivity was determined by automated flow cytometry analyzing 10' cells in each sample (ELITE, Coulter Electronics, Hialeah, FL).
Immunoglobulin assays. Frozen serum was assayed for IgG1, IgG2, IgG3, and IgG4 concentrations by enzyme-linked immunosorbent assay (ELISA) as we have previously described and was standardized using monoclonal antibodies as follows: anti-IgG l (HP6069), anti-IgG2 (HP6014), anti-lgG3 (HP6047/HP6050), and anti-IgG4 (HP6024) from Hybridoma Reagent Laboratory (Baltimore, MD)." Serum at the time of initiation of treatment (range, 42 days before to 3 days after) and 8 to 10 weeks later (range, S0 to 85 days) was selected to examine IgG subclass concentrations. Stored serum was also available from 16 normal healthy donors and was used for controls.
IgG, IgM, and IgA serum values were determined by nephelometry on a routine basis throughout the period of rIL-2 infusions. Of the 27 study patients, 23 had values available both before and 7 to 10 weeks after initiation of rIL-2 infusions.
If more than one determination was available, the values closest to the 10-week time point were included in the analysis.
Staristical analysis. Immunoglobulin concentrations and phenotype data were log-transformed for statistical calculations. Comparisons of means or geometric means were performed for normally distributed data by two-tailed t test and for nonnormally distributed data by Mann-Whitney test. Paired analyses were used for pre-to post-rIL-2 comparisons of phenotypes and subclass concentrations.
RESULTS
Patient characteristics. Twenty-seven patients aged 21 to 66 years who had received rIL-2 treatment at Dana-Farber Cancer Institute between January 1990 and October 1992 were selected for study. Patients who had stored frozen serum available before initiation of IL-2 therapy and 8 to 10 weeks after treatment were chosen. The 11 nontransplant study patients had been treated for the following malignancies: renal cell carcinoma (n = 7), colon cancer (n = 2), malignant melanoma (n = l), and testicular carcinoma (n = l). Of these 1 1 patients, 2 had received prior chemotherapy. Sixteen of the study patients had undergone BMT (10 allogeneic, five autologous, and one syngeneic) for the following underlying malignancies:
acute myelogenous leukemia (AML; n = 3), acute lymphocytic leukemia (ALL; n = 3), chronic myelogenous leukemia (CML; n = 5), non-Hodgkin's lymphoma (n = 4), and ovarian carcinoma (n = 1). Study patients initiated IL-2 infusion at a median of 8 1 days (range, 39 to 194 days) after BMT.
Immunophenotypic effects of low-dose IL-2. Phenotypic analysis of PBMC on 26 of the 27 study patients pre-and post-rIL-2 infusions is shown in Table l . One study patient did not have pre-rIL-2 phenotype data and, thus. was not included in the evaluation of rIL-2 effects on phenotype. As previously published in these patients, a significant increase in cells staining for NHKl (CD56) and FcyIII (CD16) occurred while on rIL-2 treatment.x"" The geometric mean percentage of NK cells, as defined by cells expressing CD56, increased from 18% to 54% for all study patients ( P = .0001). An increase in cells expressing CD16 (another marker of NK cells) was also noted from 21 % to 41 % ( P = .0001). The increase in NK cells during rIL-2 treatment occurred for both transplant and nontransplant patients ( Ta Immunoglobulin IgG subclass concentrations during rIL-2 therapy. IgG subclass concentrations were compared in serum samples obtained from study patients before the initiation of rIL-2 therapy and after approximately 8 to 10 weeks of treatment. In addition, sera from l6 healthy plasma donors were selected as controls, as normal values of IgG subclass concentrations can be assay-dependent.' To minimize effects due to intraassay variations, all sera were run within two assays, and pretreatment and posttreatment samples were run within the same assay.
Before the initiation of rIL-2 treatment, the geometric mean serum IgG1, IgG2, IgG3, and IgG4 concentrations of the 27 study patients were not significantly different from those of healthy controls (Table 2) . When the nontransplant and transplant patients' pretreatment values were analyzed separately, neither significantly differed from IgG subclass concentrations in the control subjects.
We next examined IgG subclass concentration changes during rlL-2 infusion treatment. A significant decrease in geometric mean IgG2 concentration from 2,017 pg/mL to 1,655 pg/mL was noted (P = .03; Table 2 ). The IgG2 decrease occurred in both patient populations: a decrease from 2,065 pg/mL to 1,717 pg/mL for transplant patients and from 1,949 ,ug/mL to 1,574 pg/mL for the nontransplant patients. Furthermore, the post-rIL-2 geometric mean IgG2 concentration was significantly lower for the study population than for normal healthy controls (P = .026). In contrast, no significant changes in serum IgGl, IgG3, or IgG4 concentrations were noted from pre-to post-rIL-2 infusion for the entire study population. In fact, the geometric mean concentration for IgG 1, the predominant IgG subclass, increased from 4,704 pg/mL to 5,280 pg/mL over the treatment period. mL before treatment and 4,855 pg/mL after rIL-2 treatment. The nontransplant patients had little change in IgGl concentrations from 5,979 pg/mL to 5,921 pg/mL after infusion.
We also compared total IgG, IgM, and IgA concentrations before and 7 to 10 weeks after initiation of rIL-2 therapy. Of the 27 study patients, 23 had values available. The geometric mean total IgG, IgM, and IgA serum concentrations were 1,095 mg/dL, 119 mg/dL, and 165 mg/dL, respectively, before treatment. After rIL-2 infusions the geometric means were not significantly different at 1,042 mg/dL, 122 mg/dL, and 161 mg/dL, respectively.
We examined the correlation of absolute number of cells expressing CD20, CD3, CD4, CD8, CD56, and CD16 of individuals with their serum IgG1, IgG2, IgG3, and IgG4 concentrations after 8 to 10 weeks of rIL-2 treatment. However, no particular lymphoid subset was correlated with any IgG subclass concentration (data not shown). Interestingly, although rIL-2 therapy resulted in a decrease in IgG2 levels and an increase in the number of circulating NK cells in most of our patients, there did not appear to be a direct inverse correlation of NK cell number with serum IgG2 concentrations after treatment.
DISCUSSION
In this study we examined the effect of rIL-2 treatment on serum IgG subclass concentrations in 27 cancer patients. Serum IgG2 subclass concentrations decreased from 2,017 to 1,655 pg/mL (P = .03) after the 8-to 10-week treatment course and resulted in a lower geometric mean concentration than in healthy controls (P = .026). The effect of rIL-2 was selective for IgG2, as no significant change occurred in concentrations of IgG1, IgG3, or IgG4. In fact, the predominant IgG subclass, IgG1, increased over the study interval.
The decrease in serum IgG2 concentration occurred in both the BMT and non-BMT patients. This is significant, as low serum IgG2 concentrations without rIL-2 infusions have been demonstrated previously at 12 to 24 months after BMT.'2,'3 Notably, the serum IgG2 concentrations of our transplant patients decreased while IgGl concentrations were increasing. This argues against natural waning of antibody after transplantation as an explanation of the IgG2 decrease. We suggest that the significant decreases in serum IgG2 concentrations for both patient populations were due to rIL-2 treatment.
It is possible that decreased serum IgG2 concentrations were the result of increased NK cells. In a model using SCID mice reconstituted with huPBMC, we recently noted that depletion of CD16-positive cells resulted in significant increases in human serum IgG2 concentrations. This datum suggests that CD16-positive cells (natural killers) downregulate human IgG2 production. Unfortunately, in our present analysis the absolute number of CD16-or CD56-positive cells induced by low-dose IL-2 did not significantly correlate with IgG2 levels. The absence of a significant inverse relationship may be merely due to sensitivity, or, perhaps, the actual number of NK cells is not as critical as the quantity of specific cytokine these NK cells elaborate. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From however, no specific effects on IgG subclass production have been shown. Human IgG2 is functionally equivalent to murine IgG3, as T cell-independent antigens induce predominantly IgG2 in humans and IgG3 in mice. Thus, IFN-y downregulation of human IgG2 may be analogous to murine LPS-induced IgG3 inhibition. Finally, alternative explanations should be considered, as we have no direct evidence that IFN-y mediates the effect. IL-2 could directly affect Bcell IgG2 production or perhaps regulate subclass selection through other cytokines elaborated by NK cells. Future studies will address the mechanism of rIL-2 regulation of human IgG2 subclass production using the reconstituted SCID model.
The clinical significance of rIL-2 infusions causing decreased IgG2 concentrations in patients receiving IL-2 is unclear. Low IgG2 concentrations have been documented to be a risk factor for polysaccharide-encapsulated pathogens in a variety of clinical settings. It has been shown that low IgG2 is associated with increased infections in infants and young children,I8 IgG2 selective deficiencies," post-BMT," vaccine failures,2° and certain ethnic populations." Increased infections during rIL-2 treatments have been documented in several studies, including the largest review of 935 rIL-2 treatment courses.22 However, typical polysaccharide-encapsulated pathogens were not reported, and Stuphylococcus uureus was the primary bacteremic isolate in this review. Low serum IgG2 concentrations have never been implicated as a risk for bacteremia with this pathogen.
In summary, rIL-2 results in significant decreases in serum IgG2 concentrations. We propose that increased NK cell numbers and increased IFN-y production are the mediators of this effect. Future studies in our SCID mouse model and in patients receiving IL-2 will address the mechanisms and clinical significance of NK regulation on human IgG2 serum concentrations.
